Abstract
Patients with cancer receive antineoplastic therapy that affect their ability to produce and maintain circulating levels of blood cells at any given time. Frequent and varied transfusion requirements necessitate a highly developed and specialized practice of blood component therapy in cancer care. In this article, the author discusses factors affecting the selection of blood components and the influence that expert critical care nurses can contribute to safe and effective transfusion therapy. Administration of leukocyte-poor or cytomegalovirus-negative erythrocytes, pheresed platelets, and granulocyte transfusions are described.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: AACN Clinical Issues: Advanced Practice in Acute and Critical Care
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
